technovalia
- Company typePrivate
- Founded-
- HeadquartersMulgrave, Australia
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
technovalia firmographics
Firmographics- Name
- technovalia
- Legal name
- Technovalia
- Website
- https://technovalia.com
- Company type
- Private
- Operating status
- Operating
- Ownership category
- akta.pro rank
technovalia industry classification
Industry- Product category
- Vaccines and Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)
Keywords
Where technovalia is headquartered
LocationHeadquarters
- HQ city
- Mulgrave
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
technovalia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Vaccine Development and Licensing: Technovalia generates revenue through development partnerships, licensing agreements, and co-development arrangements with international vaccine manufacturers. The company invests in R&D for new vaccine platforms with the goal of bringing products through clinical development to market authorization.
- Contract Research Services: Providing clinical trial management and regulatory expertise through partnerships with Australian trial sites and academic institutions. Revenue derived from government grants (MRFF) and collaborative research agreements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
technovalia product offering
Product offeringCore offering
Technovalia is a privately-owned Australian biotech company that conducts research and development of innovative vaccines and diagnostic tests for infectious diseases. The company advances gene-based vaccine candidates (DNA, mRNA, and recombinant protein) and point-of-care RT-PCR diagnostics through partnerships with academic institutions, clinical trial sites, and international manufacturers, progressing products from preclinical research through clinical trials to market authorization.
Product overview
Technovalia is a privately-owned Australian biotech company developing vaccines and diagnostics for infectious diseases. The core product portfolio includes COVIGEN, a DNA-based COVID-19 vaccine delivered via needle-free injection (Phase 1 complete); ChulaCov19 BNA159, an mRNA COVID-19 booster vaccine (Phase 2 in Australia); Pertagen, a recombinant acellular pertussis vaccine (Phase 2); and RT-PCR diagnostic tests for COVID-19 and respiratory viruses. Technovalia partners with BioNet-Asia for vaccine technology and manufacturing, and works with Australian academic institutions and health networks for clinical development. Manufacturing capabilities follow GMP PIC/S standards.
Differentiator
Problem solved
Functional benefit
Products and services
- COVIGEN A needle-free DNA-based COVID-19 vaccine developed with BioNet-Asia, encoding SARS-CoV-2 spike protein. Delivered via PharmaJet Stratis needle-free injection system. Completed Phase 1 trials in Australia evaluating safety and immunogenicity as primary immunization and booster dose.
- ChulaCov19 BNA159 A COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet. Being evaluated as a booster dose in Phase 2 clinical trials in Australia. Found safe and immunogenic in prior Phase 1/2 trials in Thailand.
- Pertagen BioNet-Asia's next-generation recombinant acellular pertussis (whooping cough) vaccine. Uses genetically engineered Bordetella pertussis bacterium with purified toxin that does not require chemical detoxification, retaining high immunogenicity. Under Phase 2 clinical trial in Australia for pertussis booster vaccination.
- RT-PCR Diagnostic Tests Rapid and cost-effective RT-PCR tests developed in collaboration with ADNucleis for point-of-care diagnostics. Includes SARS-CoV-2 detection kit that works directly from saliva samples, and assays for influenza and other respiratory viruses.
Quantifiable outcome
- First DNA-based COVID-19 vaccine to enter clinical trials in Australia
- +3 more outcomes
Companies that use technovalia
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
technovalia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
technovalia partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered core and secondary.
- Chulalongkorn UniversitycoreDevelopment partner for ChulaCov19 BNA159 mRNA COVID-19 vaccine, developed by Professor Kiat. Phase 2 trial approved in Australia in November 2022.
- BIA Separations (Sartorius)secondaryCollaboration on optimized mRNA manufacturing process development. BIA's chromatographic columns expertise combined with BioNet's genetic vaccine development for high-yield mRNA production.
- BioNet-AsiacorePrimary strategic partner and international vaccine manufacturer for gene-based vaccine development (DNA and mRNA platforms). BioNet developed COVIGEN DNA vaccine and ChulaCov19 mRNA vaccine in collaboration with Technovalia. BioNet ranked 5th globally for mRNA manufacturing capability with GMP PIC/S certified production facilities.
- Monash UniversitycoreAcademic collaboration on Chikungunya vaccine development using innovative vaccine carrier platform technology.
- University of SydneycoreLead academic institution for COVALIA Phase 1 trial of COVIGEN DNA vaccine, led by Associate Professor Nicholas Wood. Partnership includes Vax4COVID Alliance for clinical development.
- Telethon Kids InstitutecoreClinical trial site conducting COVIGEN Phase 1 trial and Pertaprime pertussis vaccine study at Perth Children's Hospital. Led by Vaccine Trials Group.
- Women's and Children's Hospital (Adelaide)coreClinical trial site for COVALIA trial and Pertaprime study through Vaccinology and Immunology Trials Unit (VIRTU), led by Professor Helen Marshall.
- Scientia Clinical ResearchcoreSydney-based clinical trial site conducting COVIGEN booster dose evaluation trial.
- Robinson Research Institute (University of Adelaide)secondaryAcademic partner contributing to pertussis vaccine research and maternal immunisation studies.
- International Vaccine Institute (IVI)secondaryInternational organization for global vaccine development and distribution support.
- Pasteur InstitutesecondaryInternational collaboration on vaccine research and development.
- University of QueenslandsecondaryCollaboration on needle-free vaccine delivery research through Advance Queensland Industry Fellowship in partnership with Vaxxas.
- VaxxassecondaryPartnership for high-density microarray patch (HD-MAP) needle-free vaccine delivery technology for University of Texas Hexapro vaccine candidate.
- PharmaJetcoreProvider of Stratis Needle-free Injection System used to deliver COVIGEN DNA vaccine via jet spray technology for clinical trials.
- ADNucleissecondaryCollaboration on development of rapid RT-PCR point-of-care diagnostic tests for SARS-CoV-2 and other respiratory viruses.
- SypharmacorePartner in Genetis consortium for establishment of Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines.
- NCIRS (National Centre for Immunisation Research and Surveillance)secondaryAustralian organization supporting immunisation research and surveillance.
- MimotopessecondaryAustralian biotech company for vaccine technology development support.
- NTX (NTX Bio)secondaryBiotechnology partner for vaccine development.
- Luina BiosecondaryAustralian biotech company for vaccine and biologics development.
- The Westmead InstitutesecondaryResearch institute for clinical and translational research in vaccines.
- WSLHD Research EducationsecondaryWestern Sydney Local Health District research education collaboration.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
technovalia competitors and assessment
Company assessmentEmerging players
- Vaxxas: Australian biotech developing high-density microarray patch (HD-MAP) needle-free vaccine delivery technology, partnered with Technovalia on University of Texas Hexapro research. Comparable because it is an Australian-stage vaccine-delivery specialist with overlapping platform and infectious disease focus.
- Arcturus Therapeutics: Clinical-stage mRNA vaccine and therapeutic developer with COVID-19 vaccine programs and additional infectious disease pipeline. Comparable as an mRNA vaccine peer at similar clinical development stage with overlapping technology platform.
Broad incumbents
- Pfizer: Global pharmaceutical leader with the BioNTech-partnered mRNA COVID-19 vaccine franchise and a broad infectious disease vaccine portfolio. Comparable as the dominant incumbent in the COVID-19 vaccine market where Technovalia's candidates compete.
- Sanofi: Global vaccines major with established respiratory and pediatric vaccine franchises including pertussis-containing products. Comparable as a large-scale vaccine incumbent that competes with Technovalia's pertussis candidate in the global booster market.
- Moderna: Global mRNA vaccine leader with an approved COVID-19 vaccine and a broad infectious disease pipeline. Comparable as a mRNA platform incumbent operating in the same infectious disease vaccine category, though at vastly greater scale and commercialization stage.
- CSL Limited: Australia's largest biotech and a major global vaccine manufacturer (including influenza and COVID-19 boosters). Comparable as a domestically headquartered Australian vaccine company with overlapping infectious disease focus and end-to-end development-to-manufacturing capability.
Direct peers
- Inovio Pharmaceuticals: Clinical-stage DNA vaccine developer with global programs in infectious disease (including COVID-19) and infectious disease immunotherapy. Directly comparable as a DNA vaccine platform peer targeting similar indications and at a similar clinical development stage.
- Sypharma: Australian biologics manufacturer and Genetis consortium partner with Technovalia for end-to-end vaccine development and production. Comparable as a co-developer and contract manufacturer within the same Australian vaccine manufacturing ecosystem.
- Novavax: Clinical-to-commercial stage recombinant protein vaccine developer with an approved COVID-19 vaccine and broader infectious disease pipeline. Comparable as a recombinant-subunit vaccine peer targeting the same pathogens and competing in the same commercial markets.
- BioNet-Asia: BioNet is Technovalia's primary strategic partner and co-developer of COVIGEN (DNA) and ChulaCov19 (mRNA) vaccines, plus the pertussis vaccine. It is directly comparable because it covers the same gene-based vaccine portfolio, GMP manufacturing, and infectious disease targets that define Technovalia's pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
technovalia social profiles
Digital presencetechnovalia financial estimates
Financial estimateRevenue estimate
Valuation estimate
technovalia leadership team
Management profileNumber of profiles
technovalia subsidiaries and ownership
Company hierarchySubsidiaries1 record
technovalia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
technovalia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about technovalia
What does technovalia do?
Technovalia is a privately-owned Australian biotech company that conducts research and development of innovative vaccines and diagnostic tests for infectious diseases. The company advances gene-based vaccine candidates (DNA, mRNA, and recombinant protein) and point-of-care RT-PCR diagnostics through partnerships with academic institutions, clinical trial sites, and international manufacturers, progressing products from preclinical research through clinical trials to market authorization.
Is technovalia a public or private company?
technovalia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was technovalia founded?
technovalia was founded in -1.
Where is technovalia based?
technovalia is headquartered in Mulgrave, Australia, in the Oceania region.
How does technovalia make money?
Two revenue lines are on record. Vaccine Development and Licensing is the primary driver. The others are contract Research Services.
Who are technovalia's main competitors?
Emerging players on record are Vaxxas and Arcturus Therapeutics. Broad incumbents are Pfizer, Sanofi, Moderna and CSL Limited. Direct peers are Inovio Pharmaceuticals, Sypharma, Novavax and BioNet-Asia.
Does technovalia have an API?
No public API is recorded for technovalia.
What industry is technovalia in?
technovalia's product category is Vaccines and Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.